Nippon Shinyaku Licenses Prulifloxacin Marketing Rights To Lee’s Pharmaceutical
This article was originally published in PharmAsia News
Kyoto-based Nippon Shinyaku announced March 3 a licensing agreement on antibacterial drug prulifloxacin with Hong Kong biopharmaceutical company Lee's Pharmaceutical Holdings, which gives Lee's the exclusive marketing rights in China for antibacterial drugs containing prulifloxacin. Nippon Shinyaku will receive an undisclosed upfront payment, milestone payments based on sales achievement and product royalties. An oral broad spectrum fluoroquinolone antibiotic developed by Nippon Shinyaku, prulifloxacin is marketed in Japan by Meiji Seika with the name Sword and by Angelini with the name Unidrox in Europe. (Click here for more - Japanese language
You may also be interested in...
HONG KONG - A famous ability to copy, combined with a chronic shortage of innovation, has long defined China's pharmaceutical industry
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.